Jonathan Hoggatt, PhD, is a biotechnology leader at Moderna, where he advances platforms and programs that translate cutting-edge science into impactful medicines. His work spans cross-functional strategy and execution across discovery through early development, with emphasis on enabling technologies that improve speed, quality, and scalability, including delivery science and AI-enabled R&D.
He previously served as Harvard Medical School faculty and directed an NIH-funded translational research program focused on hematopoietic stem cell biology, immunology, gene therapy, and regenerative medicine. His discoveries have led to multiple patents and translation toward clinical development. He is a scientific co-founder of Magenta Therapeutics and contributed to multiple programs that advanced into clinical trials. Jonathan also serves in professional leadership roles spanning gene therapy and non-viral delivery, including with the American Society of Hematology (ASH) and the American Society of Gene and Cell Therapy (ASGCT).